The prognostic role of sarcopenia and albumin in locally advanced renal cell carcinoma with IVC tumor thrombus.

Authors

null

Eric Midenberg

Emory University School of Medicine, Atlanta, GA

Eric Midenberg , Dattatraya H Patil , Alexandra Medline , Michelle Higgins , Milton Williams , Bassel Nazha , Jacqueline T Brown , Kenneth Ogan , Sarah P. Psutka , Mehmet Asim Bilen , Viraj A. Master

Organizations

Emory University School of Medicine, Atlanta, GA, Emory University, Atlanta, GA, Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, University of Alabama at Birmingham, Birmingham, AL, Emory University Department of Hematology and Medical Oncology, Atlanta, GA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Emory University School of Medicine Winship Cancer Institute, Atlanta, GA, University of Washington Medical Center, Seattle, WA, Winship Cancer Institute of Emory University, Atlanta, GA

Research Funding

No funding received

Background: Indicators of body composition and nutritional status, such as lumbar skeletal muscle index (SMI, cm2/m2) and hypoalbuminemia, are associated with adverse outcomes following surgery for localized renal cell carcinoma (RCC) but have yet to be described in patients with RCC and venous tumor thrombus. We hypothesize that preoperative sarcopenia, a severe deficit in lean muscle mass, and hypoalbuminemia will be associated with decreased overall survival (OS) and cancer specific survival (CSS) in nonmetastatic RCC patients undergoing radical nephrectomy and tumor thrombectomy. Methods: We retrospectively analyzed 103 nonmetastatic RCC patients who underwent radical nephrectomy and tumor thrombectomy from 2005 to 2020. Optimally fit BMI (kg/m2) and sex-stratified sarcopenia thresholds were calculated (BMI<30: SMI<47 for males, SMI<38 for females; BMI≥30: SMI<54 for males, SMI<47 for females). Sarcopenia and albumin risk groups were created based on their individual hazard ratios on univariable analysis and defined as low-risk (non-sarcopenic, normal albumin), medium-risk (non-sarcopenic, hypoalbuminemia), high-risk (sarcopenic, normal albumin), and very high-risk (sarcopenic, hypoalbuminemia). Associations between independent and combined sarcopenia and hypoalbuminemia (albumin<3.5 g/dL) with OS and CSS were evaluated using multivariable and Kaplan-Meier analyses. Results: Prevalence of sarcopenia and hypoalbuminemia were 51.2% and 44.7%, respectively. Median follow up time was 24.8 months and median time from preoperative imaging to surgery was 21 days. Sarcopenia was an independent predictor of OS (p=0.003) and CSS (p=0.006) whereas hypoalbuminemia was not (OS: p=0.096; CSS: p=0.718). When analyzing sarcopenia and albumin in combination, the high and very high-risk groups were significantly associated with decreased OS (high-risk: p=0.011; very high-risk: p<0.001) and CSS (high-risk: p=0.011; very high-risk: p=0.017). Kaplan-Meier curves showed a stepwise decline in median OS (p=0.0071) and CSS (p=0.0068) times with increasing risk. Conclusions: Simultaneous sarcopenia and hypoalbuminemia were associated with nearly a seven-fold decrease in OS and CSS in patients undergoing surgery for nonmetastatic RCC with IVC tumor thrombus.

Multivariable analysis of sarcopenia and albumin’s effects on OS and CSS.


Overall Survival
Cancer Specific Survival
HR (95% CI)
p-value
HR (95% CI)
p-value
Sarcopenia
3.43 (1.50-7.85)
0.003
7.81 (2.01-30.28)
0.003
Albumin
1.89 (0.89-4.01)
0.096
0.81 (0.26-2.55)
0.718
Low-Risk: Non-sarcopenic, Normal Albumin
1 (ref.)
-
1 (ref.)
-
Medium-Risk: Non-sarcopenic, Hypoalbuminemia
2.27 (0.80-6.43)
0.121
0.95 (0.18-5.08)
0.953
High-Risk: Sarcopenic, Normal Albumin
4.13 (1.38-12.37)
0.011
8.90 (1.64-48.17)
0.011
Very High-Risk: Sarcopenic, Hypoalbuminemia
6.78 (2.50-18.35)
<0.001
6.40 (1.40-29.24)
0.017

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Other

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 387)

DOI

10.1200/JCO.2022.40.6_suppl.387

Abstract #

387

Poster Bd #

J6

Abstract Disclosures

Similar Abstracts

First Author: Elaine Chang

Abstract

2024 ASCO Genitourinary Cancers Symposium

IL-6 and PIM1 expression in renal cell carcinoma.

First Author: Kimberly Stephanie Meza